A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease

Annals of Neurology

Volumn 45, Issue 5, 1999, Pages 666-668

  Papassotiropoulos, Andreas ^a   Bagli, Metin ^a   Jessen, Frank ^a   Bayer, Thomas A ^a   Maier, Wolfgang ^a   Rao, Marie Luise ^a   Heun, Reinhard ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CYTOKINE; INTERLEUKIN 6;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PATIENT SELECTION; PRIORITY JOURNAL; RISK FACTOR;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; TIME FACTORS; VARIATION (GENETICS);

EID: 0032914896     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199905)45:5<666::AID-ANA18>3.0.CO;2-3     Document Type: Article

References (19)

1. Sisodia SS, Price DL. Role of the beta-amyloid protein in Alzheimer's disease. FASEB J 1995;9:366-370
2. Egensperger R, Kosel S, von Eitzen U, Graeber MB. Microglial activation in Alzheimer disease: association with APOE genotype. Brain Pathol 1998;8:439-447
3. Mrak RE, Sheng JG, Griffin WS. Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum Pathol 1995;26:816-823
4. Brugg B, Dubreuil YL, Huber G, et al. Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. Proc Natl Acad Sci USA 1995;92:3032-3035
5. Breitner JC. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol Aging 1996;17:789-794
6. Aisen PS. Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies. Gerontology 1997;43:143-149
7. Altstiel LD, Sperber K. Cytokines in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:481-495
8. Campbell IL, Abraham CR, Masliah E, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA 1993;90:10061-10065
9. Murray RE, McGuigan F, Grant SF, et al. Polymorphisms of the interleukin-6 gene are associated with bone mineral density. Bone 1997;21:89-92
10. Duff GW. Cytokines and acute phase proteins in rheumatoid arthritis. Scand J Rheumatol 1994;100(Suppl):9-19
11. Copeland JR, Davidson IA, Dewey ME, et al. Alzheimer's disease, other dementias, depression and pseudodementia: prevalence, incidence and three-year outcome in Liverpool. Br J Psychiatry 1992;161:230-239
12. Maes M, Meltzer HY, Bosmans E, et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995;34:301-309
13. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548
14. Bowcock AM, Ray A, Erlich H, Sehgal PB. Rapid detection and sequencing of alleles in the 3′ flanking region of the interleukin-6 gene. Nucleic Acids Res 1989;17:6855-6864
15. Bauer J, Ganter U, Strauss S, et al. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res Immunol 1992;143:650-657
16. Hull M, Fiebich BL, Lieb K, et al. Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options. Neurobiol Aging 1996;17:795-800
17. Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc 1993;41:176-181
18. Breitner JC, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994;44:227-232
19. Meyer MR, Tschanz JT, Norton MC, et al. APOE genotype predicts when - not whether - one is predisposed to develop Alzheimer disease. Nat Genet 1998;19:321-322